NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ARQT Stock Alerts $8.94 0.00 (0.00%) (As of 12:41 PM ET) Add Compare Share Share Today's Range$8.86▼$9.3050-Day Range$6.90▼$12.5352-Week Range$1.76▼$15.21Volume672,707 shsAverage Volume4.68 million shsMarket Capitalization$865.48 millionP/E RatioN/ADividend YieldN/APrice Target$26.56 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arcutis Biotherapeutics alerts: Email Address Arcutis Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside197.0% Upside$26.56 Price TargetShort InterestBearish19.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 2 Articles This WeekInsider TradingSelling Shares$41,811 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.49) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.60 out of 5 starsMedical Sector636th out of 910 stocksPharmaceutical Preparations Industry288th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.89% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 28.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARQT. Previous Next 2.0 News and Social Media Coverage News SentimentArcutis Biotherapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arcutis Biotherapeutics this week, compared to 4 articles on an average week.Search InterestOnly 10 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -27% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,811.00 in company stock.Percentage Held by Insiders20.70% of the stock of Arcutis Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($2.49) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 9.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More ARQT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARQT Stock News HeadlinesApril 22, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)April 14, 2024 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.8%April 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 14, 2024 | americanbankingnews.comArcutis Biotherapeutics' (ARQT) Buy Rating Reaffirmed at Needham & Company LLCApril 12, 2024 | morningstar.comArcutis Biotherapeutics Inc Ordinary Shares ARQTApril 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)April 12, 2024 | markets.businessinsider.comEvaluating Arcutis Biotherapeutics: Insights From 5 Financial AnalystsApril 10, 2024 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial OfficerApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 10, 2024 | markets.businessinsider.comArcutis Biotherapeutics Appoints David Topper To Succeed John Smither As CFOApril 10, 2024 | marketwatch.comArcutis Biotherapeutics Names David Topper as Finance ChiefApril 10, 2024 | markets.businessinsider.comBuy Rating on Arcutis Biotherapeutics Bolstered by Projected Q1 Sales Beat and 2024 Upside PotentialApril 10, 2024 | msn.comArcutis Biotherapeutics appoints CFOApril 10, 2024 | globenewswire.comArcutis Appoints David Topper as Chief Financial OfficerApril 5, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | finance.yahoo.comSol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamMarch 28, 2024 | finance.yahoo.comArcutis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 28, 2024 | globenewswire.comArcutis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 19, 2024 | finance.yahoo.comARQT May 2024 10.000 callMarch 15, 2024 | finance.yahoo.comATHA Apr 2024 2.500 putMarch 11, 2024 | finance.yahoo.comARQT Apr 2024 12.500 callMarch 11, 2024 | finance.yahoo.comARQT Apr 2024 5.000 callMarch 11, 2024 | finance.yahoo.comARQT Apr 2024 2.500 callMarch 11, 2024 | globenewswire.comArcutis Promotes Todd Tucker to Chief Human Resources OfficerMarch 10, 2024 | globenewswire.comArcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual MeetingMarch 9, 2024 | globenewswire.comNew Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier DysfunctionMarch 5, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees296Year Founded2016Price Target and Rating Average Stock Price Target$26.56 High Stock Price Target$50.00 Low Stock Price Target$8.00 Potential Upside/Downside+196.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-262,140,000.00 Net Margins-439.79% Pretax Margin-434.57% Return on Equity-294.85% Return on Assets-78.57% Debt Debt-to-Equity Ratio2.28 Current Ratio7.08 Quick Ratio6.80 Sales & Book Value Annual Sales$59.61 million Price / Sales14.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book9.52Miscellaneous Outstanding Shares96,810,000Free Float76,773,000Market Cap$866.45 million OptionableOptionable Beta1.14 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Todd Franklin Watanabe M.A. (Age 56)President, CEO & Director Comp: $1.01MDr. Bhaskar Chaudhuri Ph.D. (Age 69)Co-Founder & Independent Director Comp: $59.67kMr. Masaru Matsuda Esq. (Age 53)J.D., Senior VP, General Counsel & Corporate Secretary Comp: $626.22kDr. Patrick E. Burnett M.D. (Age 52)Ph.D., Senior VP & Chief Medical Officer Comp: $689.95kMr. John W. Smither CPA (Age 71)Chief Financial Officer Comp: $410.75kMr. Rajvir MadanChief Digital & Technology OfficerMs. Latha VairavanVice President of Finance & Investor RelationsMs. Courtney Barton (Age 41)VP and Chief Compliance Officer & Privacy Officer Ms. Amanda SheldonHead of Corporate CommunicationsMs. Ayisha JeterHead of Marketing & Market AccessMore ExecutivesKey CompetitorsSage TherapeuticsNASDAQ:SAGEABIVAX Société AnonymeNASDAQ:ABVXLiquidiaNASDAQ:LQDAInnovivaNASDAQ:INVAZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsAMI Asset Management CorpBought 345,239 shares on 4/19/2024Ownership: 0.357%Hennion & Walsh Asset Management Inc.Bought 6,155 shares on 4/17/2024Ownership: 0.051%Los Angeles Capital Management LLCSold 46,028 shares on 4/5/2024Ownership: 0.153%Masaru MatsudaSold 3,760 sharesTotal: $41,811.20 ($11.12/share)Perceptive Advisors LLCSold 300,000 shares on 2/26/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ARQT Stock Analysis - Frequently Asked Questions Should I buy or sell Arcutis Biotherapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARQT shares. View ARQT analyst ratings or view top-rated stocks. What is Arcutis Biotherapeutics' stock price target for 2024? 8 analysts have issued twelve-month price objectives for Arcutis Biotherapeutics' stock. Their ARQT share price targets range from $8.00 to $50.00. On average, they expect the company's share price to reach $26.56 in the next year. This suggests a possible upside of 197.0% from the stock's current price. View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts. How have ARQT shares performed in 2024? Arcutis Biotherapeutics' stock was trading at $3.23 at the beginning of 2024. Since then, ARQT stock has increased by 176.8% and is now trading at $8.94. View the best growth stocks for 2024 here. Are investors shorting Arcutis Biotherapeutics? Arcutis Biotherapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 19,260,000 shares, an increase of 28.5% from the March 15th total of 14,990,000 shares. Based on an average trading volume of 4,760,000 shares, the days-to-cover ratio is presently 4.0 days. View Arcutis Biotherapeutics' Short Interest. When is Arcutis Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ARQT earnings forecast. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.08. The company earned $13.53 million during the quarter, compared to the consensus estimate of $11.78 million. Arcutis Biotherapeutics had a negative net margin of 439.79% and a negative trailing twelve-month return on equity of 294.85%. During the same period in the previous year, the firm earned ($1.18) earnings per share. What ETFs hold Arcutis Biotherapeutics' stock? ETFs with the largest weight of Arcutis Biotherapeutics (NASDAQ:ARQT) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV). When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $125 million in an initial public offering on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AMI Asset Management Corp (0.36%), Los Angeles Capital Management LLC (0.15%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARQT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.